Telomir Pharmaceuticals, Inc.
NasdaqCM · USDTelomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Analytick AI is a research platform. Output is informational and not financial advice — trade at your own risk.
Analytick AI is a product of Analytick Inc. · Rockville, Maryland, 20852, United States
© 2026 Analytick AI
Be the first to share your outlook and start the conversation with other investors in the TELO community.